Dr. Ganesh Kumar Ammannaya

5.5K posts

Dr. Ganesh Kumar Ammannaya banner
Dr. Ganesh Kumar Ammannaya

Dr. Ganesh Kumar Ammannaya

@DAmmannaya

Cardiac Surgeon, Medical Researcher & Innovator. Value Equity Investor since 21. Tweets abt Stocks are Educational & NOT Recommendations.

Karnataka/Gujarat Katılım Mart 2020
3 Takip Edilen37.2K Takipçiler
Sabitlenmiş Tweet
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
“SCIENTIFIC Approach” in Everything that You Do Liberates You From Mediocrity For Life! EDUCATION Empowers Like No Other & With Education Must Come HUMILITY! PERFECTION Comes From Repetition! Create Your Own Destiny through VISION, CONVICTION, PASSION & INEXHAUSTIBLE PATIENCE!
Dr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet media
English
61
46
367
0
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
Interesting to see. Few points here. Inventory at H1 was at all time high. ~44 Cr which may have hit around 50 Cr at Q3 going by the trend. JAN, FEB were normal months. So, in March if they were able to take advantage of existing inventory then possible to give better than expected Nos. Secondly, even with higher raw material costs if they are able to pass it on to customers being one of the largest suppliers, then it’s possible to maintain margins. I think Q4, Q1 will make things clear.
English
0
1
5
392
deepakbdk
deepakbdk@deepak_bdk·
@DAmmannaya Sir..this quarter result will be impacted due to Increases in raw material price ??
English
1
0
0
338
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
CRUDE CRASH associated with many many stocks/sectors benefiting. (Of course, Sustained Low Prices over prolonged periods a requisite) One particular MicroCap Stock that comes to my mind below for further research for the reasons of structural growth visibility in place. KESAR PETROPRODUCTS - (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further Study) NEW REVENUE Stream VISIBILITY from WASTE (BY-PRODUCT) INNOVATION: - WASTE ——> to Complex NP Fertiliser, (Contribution already STARTED in Q4 as it has gone online in late JAN) This is an IMPORT SUBSTITUTE - also, the export of Complex NP Fertiliser has been banned in China. Hence, EBIDTA margin expected to HIGH ~35-40% for this complex NP fertiliser. - WASTE ——> to Zinc Phosphate to come up NEXT in FY27 (used in manufacturing of Anti-Corrosive paints) NPM has expanded very significantly from 5% last year to 10% for 9M FY26 and management targets ~21% Margins by FY27 (as in the LATEST Presentation, the Slide image can be seen below), to be made possible by WASTE PRODUCT INNOVATION + COGEN SAVINGS DEBT reduction target - by minimum 25% in FY26 (Co has walked the talk here as already, 15% DEBT reduced, 73 to 62 Cr at H1 FY26) Excellent CASH FLOW - H1 FY26 - Rs 15.86 Cr (For a ~230 Cr Mkt Cap Co) Technically, well poised as well - LT Rounding Bottom. MT - On the verge of BO on monthly charts. (Chart Only for Academic illustration, NO targeted levels) Hence, makes a case for further in-depth study, as CAPEX CYCLE is COMPLETE & Growth phase seems to have commenced here in FY26 with FY27 promising to be robust. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further Study)
Dr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet media
Dr. Ganesh Kumar Ammannaya@DAmmannaya

Wave 5 has taken off well since the quoted tweet.

English
4
35
225
32.1K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
Wave 4 - 50% Retracement of (15,183 to 26,373) works out to 20,778 April 2025 Low - 21,743 These 2 Key SUPPORTS, if 22,283 broken. Wave 5 = Wave 1 = 11,093 31,871 / 32,836 Picture still remains same as before (no change, just delay) in my opinion.
Dr. Ganesh Kumar Ammannaya tweet media
English
12
12
165
30.3K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
NIFTY 26,050 to 23,000-23,200. But, this one turned out a DEFENSIVE bet heading HIGHER by 10% in the same period. Few pockets in SMALL CAPs can still act so ahead, where there is a structural story ahead.
Dr. Ganesh Kumar Ammannaya tweet media
Dr. Ganesh Kumar Ammannaya@DAmmannaya

FERMENTA BIOTECH - Interesting Stock Idea that merits further research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further in-depth Study) Currently trading at merely 8 PE on TTM EPS Rs 38.06 (Historical PE - last 10 yrs Mean PE 19.40, Lifetime avg PE 15). ROCE 23%, ROE 24.9% (EBIDTA margin H1 FY26 25.9%) with excellent H1/Q2 FY26 Nos. LATEST Development - (first 2 images) of MAJOR CAPEX. VITAMIN D3 Moat - World leader (among Top 3 & the Only Indian Co) in Vitamin D3 (niche player) Recent PATENT for its plant based (Vegan) Vitamin D3 expected to significantly expand margins as these command much higher premiums (image 3 gives a very rough idea about premium margins), expected to be a Key Growth Driver in core business, also for which CAPEX is primarily planned for this FY26 & FY27. Increasing awareness worldwide about role of Vitamin D3 in virtually every organ system of human body, ill effects of its deficiency such as increased cardiovascular risks, infertility & recent European studies showing improved survival in Cancer patients on Vitamin D3 supplements, apart from proven benefits such as anti-ageing, anti cancer & immunity boosting effects, one of the mainstays in the treatment of osteoporosis (weak bones particularly elderly) etc., augurs well for wide scale use across all geographies. Scale Up in GERMAN Operations - H1 FY26 revenue 34.3 Cr (Up 194% YoY) & EBIDTA 7.7 Cr (Up 103% YoY). - Overall EU share increasing to 29% (from 27%), - US share dropping to 13% (from 15%). - Rest Domestic - 40%, - Others-18% Expanding to Other Vitamins - Vitamins K1 (one of the few global suppliers), Vitamin- fortified Rice (Govt schemes, like in AP) with plans of Vitamin A, E over next 5 yrs. MoU with NIFTEM to establish Centre of excellence for Food Fortification enhancing public nutrition. Additionally, Environmental solutions including Waste WATER management. fermentabiotech.com/environmental-… Co seems to be focusing keenly on this segment as evidenced by further investment of Rs 7.9 Cr more recently in the subsidiary. Result of this increased focus on Environmental Solutions Subsidiary Visible as - H1 Revenue up 127% in H1 FY26 (to 15.1 Cr, from 6.6 Cr YoY). Co has been unlocking Value from Real Estate well. Has excellent LAND BANK primarily in Thane 5.5 acres (apart from Thane One) & 45 acres in Takwe, Pune, alongside steady leasehold income like Thane One. Debt levels cut down more than half from 239 to 112 Cr, with Turnaround Positive Cash Flow. Promoter stake has increased steadily from 59 to 64% over last 2 yrs with No of Retail shareholders coming down from 17 K to 13 K during times of extreme stress for the Co until the recent Turnaround. Technically, C&H with probably a “W” shaped Bottom (256, that’s a DOUBLE BOTTOM, also the Key Support) in the handle seems supportive & Key multi-year resistance being (also ATH) ~450, which it tested 2-3 times in the last 7 yrs. Thus, makes a case for further in-depth research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further Study)

English
12
21
164
22.1K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
KEY HOLE HEART BYPASS - MINI OPCAB (through a Small 10 CM cut in front of Lower Chest) Performed for the FIRST TIME in ASIA!
Dr. Ganesh Kumar Ammannaya tweet media
English
33
21
471
33.6K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
BSE SMALLCAP INDEX - Yet another “Breakout attempt” loading? Early to call, but some sort of a W bottoming could be in progress with some pre-Budget rally in the offing. Follow up action crucial next week to confirm this and the upper orange bar is ~4-5% away.
Dr. Ganesh Kumar Ammannaya tweet media
English
5
9
165
16.4K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
A Simple MASTER STROKE that can potentially achieve multiple Wins for the Indian Economy & the Govt. alike - Wins such as - 1. Get Rupee-Dollar equation back in control with FII inflows in pouring. 2. Have a Big increase in Net Direct tax collection for at least coming 2-3 FYs simply by much better Stock market performance (as this FY expecting minimal STCG/LTCG Tax collection from equities for the Govt.!). 3. Happy Electorate. All these can be achieved by getting LTCG Tax back to 10% (if not 0% like how it was During Modi-1 2014-2017), STCG Tax back to 15%. Also, Why the above solution can work out Wonders is you already have a precedent example - as to how Consumer Demand picked up massively reaching new Frenzy this festive season post GST cut. FIIs have a beautiful entry point here with $ 90.50-91 ₹, and will simply lap up Indian equity. Not to forget GDP growth 8.2% + LOW Inflation make INDIA the perfect Investment destination. Just a small push needed from the Govt. for a very Simple Solution. Kindly give serious consideration to this. @FinMinIndia @PMOIndia @nsitharaman @nsitharamanoffc #Budget2026
Raghav Chadha@raghav_chadha

𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗗𝗼𝗺𝗲𝘀𝘁𝗶𝗰 𝗖𝗮𝗽𝗶𝘁𝗮𝗹 must be 𝗥𝗲𝘄𝗮𝗿𝗱𝗲𝗱, 𝗻𝗼𝘁 𝗣𝗲𝗻𝗮𝗹𝗶𝘀𝗲𝗱. I explained in Parliament how Investment in India remains heavily taxed, and why it needs to change.

English
14
112
492
41.2K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
FERMENTA BIOTECH - Interesting Stock Idea that merits further research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further in-depth Study) Currently trading at merely 8 PE on TTM EPS Rs 38.06 (Historical PE - last 10 yrs Mean PE 19.40, Lifetime avg PE 15). ROCE 23%, ROE 24.9% (EBIDTA margin H1 FY26 25.9%) with excellent H1/Q2 FY26 Nos. LATEST Development - (first 2 images) of MAJOR CAPEX. VITAMIN D3 Moat - World leader (among Top 3 & the Only Indian Co) in Vitamin D3 (niche player) Recent PATENT for its plant based (Vegan) Vitamin D3 expected to significantly expand margins as these command much higher premiums (image 3 gives a very rough idea about premium margins), expected to be a Key Growth Driver in core business, also for which CAPEX is primarily planned for this FY26 & FY27. Increasing awareness worldwide about role of Vitamin D3 in virtually every organ system of human body, ill effects of its deficiency such as increased cardiovascular risks, infertility & recent European studies showing improved survival in Cancer patients on Vitamin D3 supplements, apart from proven benefits such as anti-ageing, anti cancer & immunity boosting effects, one of the mainstays in the treatment of osteoporosis (weak bones particularly elderly) etc., augurs well for wide scale use across all geographies. Scale Up in GERMAN Operations - H1 FY26 revenue 34.3 Cr (Up 194% YoY) & EBIDTA 7.7 Cr (Up 103% YoY). - Overall EU share increasing to 29% (from 27%), - US share dropping to 13% (from 15%). - Rest Domestic - 40%, - Others-18% Expanding to Other Vitamins - Vitamins K1 (one of the few global suppliers), Vitamin- fortified Rice (Govt schemes, like in AP) with plans of Vitamin A, E over next 5 yrs. MoU with NIFTEM to establish Centre of excellence for Food Fortification enhancing public nutrition. Additionally, Environmental solutions including Waste WATER management. fermentabiotech.com/environmental-… Co seems to be focusing keenly on this segment as evidenced by further investment of Rs 7.9 Cr more recently in the subsidiary. Result of this increased focus on Environmental Solutions Subsidiary Visible as - H1 Revenue up 127% in H1 FY26 (to 15.1 Cr, from 6.6 Cr YoY). Co has been unlocking Value from Real Estate well. Has excellent LAND BANK primarily in Thane 5.5 acres (apart from Thane One) & 45 acres in Takwe, Pune, alongside steady leasehold income like Thane One. Debt levels cut down more than half from 239 to 112 Cr, with Turnaround Positive Cash Flow. Promoter stake has increased steadily from 59 to 64% over last 2 yrs with No of Retail shareholders coming down from 17 K to 13 K during times of extreme stress for the Co until the recent Turnaround. Technically, C&H with probably a “W” shaped Bottom (256, that’s a DOUBLE BOTTOM, also the Key Support) in the handle seems supportive & Key multi-year resistance being (also ATH) ~450, which it tested 2-3 times in the last 7 yrs. Thus, makes a case for further in-depth research. (NOT A RECOMMENDATION / NOT INVESTMENT ADVICE, Merely a Stock Idea for further Study)
Dr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet media
English
9
79
456
68.8K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
About 40% Spurt with ATH! NONE of my tweets constitute Advice. NO BUY/SELL Recommendations. One must be wise to NOT CHASE ideas at Peaks no matter how good the story is. This is Universal & applies to almost every idea/stock. My tweet is very general, merely cautionary in nature & has no adverse bearing on any stock idea 🙏 (The time to Get Interested in stocks is when they are INVISIBLE to most)
Dr. Ganesh Kumar Ammannaya@DAmmannaya

Successful Investment also needs plentiful luck. Latest example-

English
5
7
109
25.3K
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
Proud to be invited to the “INTERNATIONAL CORONARY CONGRESS 2025”, to present my work regarding Rapid Recovery after Heart Bypass (CABG) in NEW YORK, this December.
Dr. Ganesh Kumar Ammannaya tweet media
Dr. Ganesh Kumar Ammannaya@DAmmannaya

Proud to Publish my Case Series in “AMERICAN JOURNAL OF CASE REPORTS”, amjcaserep.com/abstract/index… which carry 3 “WORLD’s FIRST-ever” to be reported in Medical Literature. 1.World’s 1st documented case of simultaneous Coronary artery Endarterectomy (CAE) + Pericardiectomy. Furthermore, this was done in a patient with very low EF 20-25% - Discharged on post operative 2nd day. 2.Emergency CABG, within 12 hrs of CAG - Discharged on post operative 2nd day, 1st such case documented in medical literature. 3.CABG in Single Kidney patient with borderline renal function S.Creat 1.7 - Discharged on post operative 2nd day, again 1st such case documented in medical literature. All 3 patients with successful 1 year follow up, at the time of submitting the article and now 17 months successful follow up till date 🙏🙏

English
32
10
164
24.6K
Raj
Raj@thakkarrajendra·
@DAmmannaya Congratulations and all the best for your presentation. You are holding India high!!!
English
1
0
2
308
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
My apologies for not being able to see/reply to direct messages (DMs) earlier which had piled up enormously over last many months. Trying my best to see/reply to as many as possible. Sorry again, will try my best 🙏 Any message needing quick/urgent attention, may send again. Thank you.
English
3
8
103
14.6K
aman kumar
aman kumar@amaniable·
@DAmmannaya Sir your bio says Karnataka/Gujarat .. where in Karnataka can we meet you for checkups ?
English
1
0
2
652
Dr. Ganesh Kumar Ammannaya
Dr. Ganesh Kumar Ammannaya@DAmmannaya·
Feel truly Blessed to be so deeply loved & revered by My Dearest Patients 🙏 It’s incredibly humbling & drives my passion to keep serving each & everyone 24/7. As a matter of fact, I’m available for each every patient of mine over my personal mobile 24/7. Even after giving them such liberty with with direct 1 to 1 access 24/7, yet, they are so ultra-sweet as to ensure never to bother me unnecessarily or at max just drop a WhatsApp message & call only & only when there’s some dire emergency. Grateful for such lifetime relationships built over unbreakable trust 🙏 (While I have physically touched/healed their Hearts, they all have touched & won my heart as well!! Proud to be a lifetime part of 1500-2000 such families ♥️🙏)
Dr. Ganesh Kumar Ammannaya tweet mediaDr. Ganesh Kumar Ammannaya tweet media
Dr. Ganesh Kumar Ammannaya@DAmmannaya

Very Humbling for me as invaluable Blessings from My Dear Patients pour 🙏🙏 Home grown/home made tokens of gratitude such as these overwhelm. Truly Grateful for all the Love 🙏🙏

English
12
12
186
33.1K